Last reviewed · How we verify
Arm B: Rituxan®/Mabthera®
Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.
At a glance
| Generic name | Arm B: Rituxan®/Mabthera® |
|---|---|
| Sponsor | Dr. Reddy's Laboratories Limited |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers immune-mediated destruction of B cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This B cell depletion reduces autoimmune and malignant B cell populations.
Approved indications
- Non-Hodgkin's lymphoma (B-cell)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Infections
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Fatigue
- Fever
- Nausea
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (PHASE1, PHASE2)
- Belimumab With Rituximab for Primary Membranous Nephropathy (PHASE2)
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (PHASE2)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (PHASE4)
- Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (PHASE3)
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm B: Rituxan®/Mabthera® CI brief — competitive landscape report
- Arm B: Rituxan®/Mabthera® updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI